Onoact (landiolol) / Ono Pharma - LARVOL DELTA

Budget Impact Analysis of Landiolol, an Ultra-short-acting Beta-antagonist, for the Treatment of Sepsis/SIRS-related Supraventricular Tachycardia in the ICU: US Perspective (ASHP 2025) - No abstract available

HEOR • Cardiovascular • Infectious Disease • Septic Shock • Ventricular Tachycardia

Cost-Effectiveness Analysis of Landiolol, an Ultra-short-acting Beta-antagonist, for Treatment of Sepsis/SIRS-related Supraventricular Tachycardia in the ICU: US Perspective (ASHP 2025) - No abstract available

Cost effectiveness • HEOR • Cardiovascular • Infectious Disease • Septic Shock • Ventricular Tachycardia

Cost-Effectiveness Analysis of Landiolol, an Ultra-short-acting Beta-antagonist, for Treatment of Sepsis/SIRS-related Supraventricular Tachycardia in the ICU: US Perspective (ASHP 2025) - "Hosted by the Section of Clinical Specialists and Scientists"

Cost effectiveness • HEOR • Cardiovascular • Infectious Disease • Septic Shock • Ventricular Tachycardia

Comparison of Esmolol Versus Landiolol on Mortality in Adult Patients With Sepsis: A Systematic Review and Network Meta-Analysis. (PubMed, Crit Care Med) - "Among patients with sepsis treated with β-blockers, esmolol probably improves clinical outcomes compared with SOC. However, the effect of landiolol remains uncertain due to the low certainty of evidence. Esmolol may confer a relative clinical advantage over landiolol, but further studies are needed to confirm this finding and elucidate the underlying mechanisms."

Journal • Retrospective data • Infectious Disease • Septic Shock

The controversies in the clinical management of β-blockers in acute heart failure induced by rapid atrial fibrillation: A narrative review. (PubMed, Am Heart J Plus) - "AF management guidelines generally recommend considering the addition of β-blockers when digoxin-like drugs (such as cedilanid) fail to effectively control the ventricular rate...This article systematically reviews the clinical management strategies under this guideline contradiction, including: (1) Different recommendations on ventricular rate control and the use of β-blockers in domestic and international guidelines for AF and HF; (2) A pooled analysis of relevant research evidence; (3) Application strategies of β-blockers (especially short-acting agents esmolol and landiolol) in the acute phase...Although some studies and consensus articles have focused on the management of rapid AF complicated by HF, there is currently a lack of systematic reviews on this issue. Therefore, the writing of this review has important academic value and clinical guiding significance, providing a reference for treatment decisions in this special population."

Journal • Review • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure

Low dose of landiolol does not prevent postoperative atrial fibrillation after cardiac surgery in non-Asian patients: a multicentre randomised study. (PubMed, Br J Anaesth) - P3 | "In non-Asian patients undergoing cardiac surgery with CPB, a low-dose 24-h infusion of landiolol, used as a bridge to oral beta-blockers, did not reduce the incidence of postoperative atrial fibrillation."

Journal • Atrial Fibrillation • Cardiovascular • Critical care

A Case Report of Thyroid Storm with Cardiovascular Collapse After Propranolol Administration. (PubMed, Clin Pract Cases Emerg Med) - "Beta-blocker use in the management of thyrotoxicosis can potentially cause cardiovascular collapse. We suggest consideration of shorter acting beta blockers, such as esmolol or landiolol."

Journal • Cardiomyopathy • Cardiovascular • Critical care • Gastroenterology • Gastrointestinal Disorder • Grave’s Disease • Infectious Disease • Myocardial Infarction

The art of conducting a good pilot study: a discussion of the BETA-ARREST pilot trial. (PubMed, Resusc Plus) - "In this paper, we provide a critical appraisal of the BETA-ARREST trial "Landiolol for Refractory Ventricular Fibrillation in Out-of-hospital Cardiac Arrest: a Randomized, Double-blind, Placebo-controlled, Pilot Trial" by Gelbenegger et al. 2024, and discuss what constitutes a good pilot study."

Clinical • Journal • Cardiovascular

Clinical effect of dexmedetomidine combined with landiolol hydrochloride on cerebral oxygen metabolism and inflammatory response in patients with severe craniocerebral injury. (PubMed, BMC Anesthesiol) - No abstract available

Journal • Inflammation

Protective impact of landiolol against acute lung injury following hemorrhagic shock and resuscitation in rats. (PubMed, Mol Med Rep) - "In conclusion, landiolol administration after HSR reduced lung inflammation and apoptosis, suggesting a potential improvement in tissue damage. Furthermore, pAMPKα activation in the HSR/landiolol group may be the mechanism underlying the pulmonary protective effects of landiolol."

Journal • Preclinical • Acute Lung Injury • Hematological Disorders • Hypotension • Inflammation • Oncology • Pneumonia • Respiratory Diseases • CASP3 • TNFA

CARDIOVASCULAR EFFECTS OF LANDIOLOL IN INTENSIVE CARE PATIENTS: A RETROSPECTIVE SAFETY ANALYSIS (CHEST 2025) - "In our experience, landiolol appears to be a safe option for treating supraventricular tachyarrhythmia in ICU patients. Careful dose titration to target HR, as recommended by atrial fibrillation guidelines, can be achieved with relatively low doses of landiolol, with minimal impact on blood pressure and stable vasopressor requirements over time. CLINICAL IMPLICATIONS: Landiolol appears to be a safe option for treating supraventricular tachyarrhythmia in ICU patients."

Retrospective data • Atrial Fibrillation • Cardiovascular • Critical care • Septic Shock • Ventricular Tachycardia

COMPARATIVE EFFECTIVENESS OF BETA BLOCKERS ON MORTALITY AND CLINICAL OUTCOMES IN ADULTS WITH SEPTIC SHOCK: A COMPREHENSIVE SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS (CHEST 2025) - "Esmolol appears to be the most effective beta blocker for reducing mortality and improving clinical outcomes in septic shock. It showed significant reductions in 28-day mortality, ICU mortality, heart rate, and serum lactate levels, as well as a shorter ICU stay. In comparison, landiolol demonstrated less effectiveness."

Clinical data • HEOR • Retrospective data • Review • Metabolic Disorders • Septic Shock

Differential Mortality Benefit of Beta-blockers in Septic Shock: A Subgroup Meta-analysis. (PubMed, Indian J Crit Care Med) - "Esmolol appears beneficial, while Ivabradine and Landiolol show no clear mortality advantage. Differential Mortality Benefit of Beta-blockers in Septic Shock: A Subgroup Meta-analysis. Indian J Crit Care Med 2025;29(8):704-707."

Journal • Retrospective data • Cardiovascular • Septic Shock

Prevention and Treatment of New-Onset Postoperative Atrial Fibrillation in the Acute Care Setting: A Narrative Review. (PubMed, J Clin Med) - "Considering on the one hand its serious adverse effects and complex drug interactions, and on the other hand discrepancies among recent international guidelines, the indications of amiodarone to both prevent and treat POAF should be reserved to patients at high risk of POAF only, or patients with hemodynamic instability and/or severely reduced left ventricular ejection fraction. Given their efficient and safe profile, ultra-short-acting intravenous beta-blockers like esmolol or landiolol could be preferentially used in acute care patients. Besides waiting for the results of ongoing RCTs in cardiac and noncardiac surgery, the use of oral anticoagulation in patients with POAF should take into account the individualized thromboembolic/hemorrhagic risk ratio."

Journal • Review • Atrial Fibrillation • Cardiovascular • Hematological Disorders

Hemodynamic Changes Following Landiolol Initiation in Patients With Critical Illness Who Developed Tachycardia During Dobutamine Infusion: A Retrospective Observational Study. (PubMed, Cureus) - "Conclusions Landiolol effectively reduced HR without reducing MAP in critically ill patients with dobutamine-induced tachycardia. Furthermore, landiolol may promote rhythm control and improve metabolic parameters such as lactate levels."

Journal • Observational data • Retrospective data • Atrial Fibrillation • Cardiovascular • Critical care • Hypotension

Ahnak and Nckap1l as potential diagnostic biomarkers and therapeutic targets in Landiolol-mediated sepsis treatment. (PubMed, Comput Biol Chem) - "Ahnak and Nckap1l are potential diagnostic biomarkers and targets for therapeutic intervention in landiolol-induced sepsis following administration of Landiolol. Nckap1l can be used for endotype analysis of sepsis."

Biomarker • Journal • Infectious Disease • Septic Shock

Anesthesia management for a case of acute myocardial infarction with moderate to severe aortic valve stenosis undergoing total gastrectomy (ASA 2025) - "During the operation, alfentanil was pumped to control stress reaction, and landiolol was used to control ventricular rate. After the operation, epidural analgesia was used, and the patient recovered smoothly and was discharged from the hospital."

Clinical • Anesthesia • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Heart Failure • Myocardial Infarction

A Multicentre Observational Study on Landiolol Use, Efficacy, and Safety in European Patients with Supraventricular Arrhythmia (Landi-UP). (PubMed, Eur Heart J Acute Cardiovasc Care) - "In European clinical practice, landiolol dosing adhered to product information recommendations. Landiolol was effective in controlling HR with minimal impact on BP. The treatment was well tolerated, and no new safety signals were identified. These findings support the efficacy and safety of landiolol across diverse clinical settings in Europe."

Journal • Observational data • Atrial Fibrillation • Cardiovascular

Targeted Heart Rate Control with Landiolol in Hemodynamically Unstable, Non-Surgical Intensive Care Unit Patients: A Comparative Study. (PubMed, Medicina (Kaunas)) - " Landiolol achieved more effective HR control than standard therapy without adversely affecting BP stability. These findings suggest that landiolol may be a feasible and effective option for HR control in ICU CIP."

Clinical • Journal • Atrial Fibrillation • Cardiovascular • Critical care • Septic Shock

LANTA-P: LANdiolol to Avoid TAchycardia in Patients at Risk for Cardiovascular Events Undergoing Major Non-cardiac Surgery (clinicaltrials.gov) - P4 | N=114 | Not yet recruiting | Sponsor: Insel Gruppe AG, University Hospital Bern

New P4 trial • Cardiovascular

From Evidence to Bedside: The Role of Short-Acting β-Blockers in Sepsis Care. (PubMed, Cardiol Rev) - "This review synthesizes current data on the safety and efficacy of short-acting, cardioselective β-blockers (BBs), particularly esmolol and landiolol, in septic shock. Future multicenter trials are needed to validate its efficacy and establish clinical guidelines. Clinicians should remain cautiously optimistic when considering BBs for select patients with refractory tachycardia postresuscitation, ideally within structured protocols or ongoing research efforts."

Journal • Cardiovascular • Infectious Disease • Septic Shock

An exploratory study of landiolol plus amiodarone versus amiodarone monotherapy in paediatric junctional ectopic tachycardia after surgery. (PubMed, Cardiol Young) - "In this retrospective analysis, combined landiolol and amiodarone therapy demonstrated a shorter time to heart rate control compared to amiodarone alone, especially when landiolol was initiated first. These findings require confirmation in prospective studies."

Journal • Monotherapy • Cardiovascular • Hypotension • Pediatrics

Utility of perioperative beta blocker therapy in patients undergoing cardiac surgery (ESC-WCC 2025) - "Subgroup analysis shows this association was primarily with use of IV Landiolol and with a non-statistically significant trend toward lower risk of AFib in patients initiated or maintained on oral beta blockers (OR 0.29, 95% CI 0.20-0.41; p<0.01; OR 0.62, 95% CI 0.33-1.16; P=0.06)...Discussion This meta-analysis demonstrates that in patients who are undergoing cardiac surgery, preoperative initiation of beta-blockers, particularly IV Landilol, or continuation of chronic beta-blockers is associated with a lower risk of adverse cardiovascular outcomes, particularly post-operative AFib and SVT. The use of beta-blockers may also be associated with a mortality benefit, however additional high-quality studies with extended follow-up time and monitoring are needed to fully elucidate this association."

Clinical • Surgery • Atrial Fibrillation • Cardiovascular • Ventricular Tachycardia

LANdiolol MIcrocirculatory Effects During Septic chOc (MILANOS) (clinicaltrials.gov) - P3 | N=44 | Recruiting | Sponsor: Assistance Publique - Hôpitaux de Paris | Trial completion date: Jan 2024 ➔ Jul 2026 | Trial primary completion date: Jan 2024 ➔ Jul 2026

Trial completion date • Trial primary completion date • Septic Shock

HyperBetashock: Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility (clinicaltrials.gov) - P3 | N=360 | Recruiting | Sponsor: Centre Hospitalier Universitaire, Amiens | Trial completion date: Mar 2026 ➔ Sep 2027 | Trial primary completion date: Jun 2025 ➔ Jun 2027

Trial completion date • Trial primary completion date • Cardiovascular • Septic Shock